This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lewis, S. J. Search for Related Content PubMed PubMed Citation Articles by Lewis, S. J.

Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) trial

Sandra J. Lewis, MD, FACC^a, Frank M. Sacks, MD^*, Jayne S. Mitchell, MS, ANP^a, Cara East, MD, Stephen Glasser, MD, FACC, Sheren Kell, MD, Rebecca Letterer, RN, BSN^||, Marian Limacher, MD, FACC^#, Lemuel A. Moye, MD, PhD^**, Jean L. Rouleau, MD, FACC, Marc A. Pfeffer, MD, PhD, FACC^*, Eugene Braunwald, MD, FACC^* for the CARE Investigators

^a Legacy Good Samaritan Hospital, Portland Cardiovascular Institute, Portland, Oregon, USA
^* Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
Baylor University Medical Center, Dallas, Texas, USA
University of South Florida, Tampa, Florida, USA
University of Alabama, Birmingham, Alabama, USA
^|| University of Washington Medical Center, Seattle, Washington, USA
^# University of Florida Medical Center, Gainesville, Florida, USA
^** University of Texas School of Public Health, Houston, Texas, USA
Montreal Heart Institute, Montreal, Quebec, Canada

View larger version (13K): [in a new window]   Figure 1 Combined coronary events in women and men treated with placebo.

View larger version (15K): [in a new window]   Figure 2 Coronary events in women and men treated with pravastatin or placebo (overall risk reduction: 46% for women, 20% for men, p = 0.001 for both).